

Notice of Allowability

1. Applicants' amendment and arguments filed December 21, 2006 in response to Non-Final Office Action mailed June 30, 2006 is acknowledged.
2. Applicants arguments were considered in the light of the amendment to the claims and the availability of numerous genes encoding the upper and lower isoprenoid pathway in the Genbank (Tables 2 & 3), and were found to be persuasive, allowing the rejections under 112 first paragraph (enablement and written) be withdrawn.
3. Claims 1-3 & 7-16 are present and under consideration in this application.
4. Claims 1-3, 7-10, 14 & 16 are allowed, subject to the following Examiner's Amendment.
5. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was not required.

This application is in condition for allowance except for the presence of claims 11-13 & 15, non-elected without traverse. Accordingly, claims 11-13 & 15 are canceled.

Amend claims as follows (typographical):

LC
3/15/07
Claims 2, ³7, 8, 9, 10, 14 & 16, recite the word 'Claim or Claims' with an uppercase 'C' in the middle of a sentence. Delete the uppercase 'C' in the middle of a sentence for all these claims, and replace with a lowercase 'c'.